Stockscreener 앱 받기
20.35
4.41%
0.86
시장 영업 전:
21.40
1.05
+5.16%
전일 마감가:
$19.49
열려 있는:
$19.57
하루 거래량:
889.50K
Relative Volume:
0.64
시가총액:
$178.39M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-1.8073
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
+2.57%
1개월 성능:
-15.94%
6개월 성능:
+14.20%
1년 성능:
+22.96%
1일 변동 폭
$19.57
$20.58
1주일 범위
$18.53
$20.58
52주 변동 폭
$7.31
$130.00
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
20.35 | 170.85M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.17 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.58 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.31 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
829.83 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.02 | 33.75B | 398.11M | -1.03B | -868.57M | -5.7032 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
How to build a dashboard for Tonix Pharmaceuticals Holding Corp. stockOil Prices & Capital Protection Trade Alerts - newser.com
Is Tonix Pharmaceuticals Holding Corp. stock trading at a premium valuationMarket Sentiment Summary & Precise Swing Trade Alerts - newser.com
Sentiment analysis tools applied to Tonix Pharmaceuticals Holding Corp.M&A Rumor & Safe Entry Trade Reports - newser.com
Tonix Pharmaceuticals Holding Corp. stock trend forecastTrade Entry Report & Reliable Price Breakout Signals - newser.com
Tonix’s fibromyalgia drug shows significant pain reduction in study - Investing.com
How to recover losses in Tonix Pharmaceuticals Holding Corp. stockTrade Exit Report & Low Drawdown Trading Strategies - newser.com
Tonix’s fibromyalgia drug shows significant pain reduction in study By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Unveils Positive Trial Results for Tonmya - GuruFocus
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence - The Manila Times
Tonix PharmaceuticalsPrelim Q3 net revenue from product sales $3.3 millionSEC filing - MarketScreener
Tonix (Nasdaq: TNXP) reports Phase 3 Tonmya fibromyalgia data: Week 14 pain reduction - Stock Titan
Is Tonix Pharmaceuticals Holding Corp. stock a safe haven assetEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
First patient dosed in MGH-Led FOCUS study of Tonix’s investigational intranasal Oxytocin product - Proactive financial news
Understanding Momentum Shifts in (TNXP) - news.stocktradersdaily.com
Tonix: Assessing Tonmya's Commercial Potential Ahead Of Q4 2025 Launch - Seeking Alpha
Tonix Pharmaceuticals (TNXP) Launches New Study for Rare Endocri - GuruFocus
Can Tonix Pharmaceuticals Holding Corp. recover in the next quarterPortfolio Risk Report & Real-Time Volume Spike Alerts - newser.com
Tonix (Nasdaq: TNXP) doses first patient in MGH FOCUS AVP-D study testing 6 IU and 24 IU - Stock Titan
Tonix Pharmaceuticals Holding Corp. stock daily chart insightsTrade Risk Report & Daily Price Action Insights - newser.com
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence - The Manila Times
Tonix Pharmaceuticals Announces Poster Presentation of Tonmya™ at 2025 American College of Rheumatology Convergence - Quiver Quantitative
Tonix Pharma (Nasdaq: TNXP) to present Tonmya fibromyalgia data at ACR 2025 on Oct 27 - Stock Titan
What analysts say about Tonix Pharmaceuticals Holding Corp stockSmall Cap Stock Opportunities & Small Investment Trading Growth - earlytimes.in
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
2.88%
자본화:
|
볼륨(24시간):